A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|July 6, 2015
Should Drug Approval Decisions Consider Cost?
A newly approved cystic fibrosis drug has an annual wholesale cost of $259,000.
Advertisement
A newly approved cystic fibrosis drug has an annual wholesale cost of $259,000.
J.PMorgan Chase estimated that global sales of this drug could teach $1.6 billion next year and $4.2 billion by 2020. That's a lot of money for a medication that some members of an FDA advisory committee believed had modest effectiveness.
This drug’s hefty price tag raises a few questions, including:
- How long can our health care system sustain high prices for drug that only benefit a small number of patients?
- Will some type of drug rationing result from the high costs?
- Will there be legislation that requires drug approvals based on cost effectiveness?
What do you think?
Advertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5